Mitoxantrone in secondary progressive multiple sclerosis: A review of toxicity in 41 patients

Therapy

Volumn 4, Issue 1, 2007, Pages 55-58

  Peak, Scott ^a   Tsao Wei, Denice D ^c   Chamberlain, Marc C ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Mitoxantrone; Secondary progressive multiple sclerosis

Indexed keywords

ANTIBIOTIC AGENT; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON BETA SERINE; MITOXANTRONE; T LYMPHOCYTE ANTIBODY;

ADULT; AGED; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CONVALESCENCE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; EXPANDED DISABILITY STATUS SCALE; FEBRILE NEUTROPENIA; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; INJECTION SITE EXTRAVASATION; INJECTION SITE REACTION; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NEUTROPENIA; PATIENT MONITORING; PERIANAL ABSCESS; REVIEW; SIDE EFFECT; SKIN TRANSPLANTATION; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

EID: 33847333738     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.1.55     Document Type: Review

References (9)

1. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 61, 1332-1338 (2003).
2. Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE: Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult. Scler. 9, 59-62 (2003).
3. Gonsette RE: Mitoxantrone immunotherapy in multiple sclerosis. Mult. Scler. 1, 329-332 (1996).
4. Ghalie RG, Edan G, Laurent M et al: Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59, 909-913 (2002).
5. De Castro S, Cartoni D, Milleflorini E et al.: Noninvasive assessment of mittoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J. Clin. Pharmacol. 35, 627-632 (1995).
6. Gonsette RE: A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis. Expert Opin. Pharmacother. 5(4), 747-765 (2004).
7. Gonsette RE: Mitoxantrone in progressive multiple sclerosis: when and how to treat? J. Neurol. Sci. 206, 203-208 (2003).
8. Ghalie RG, Mauch E, Edan G et al.: A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult. Scler. 8(5), 441-445 (2002).
9. Edan G, Brochet B, Clanet M et al.: Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients: a 4 year mean follow-up study. Neurology 62(Suppl. 5), A493 (2004).